Elastase Inhibitory Activity of Airway α1-Antitrypsin is Protected by Treatment with a Catalytic Antioxidant in a Baboon Model of Severe Bronchopulmonary Dysplasia

Çagatay Karaaslan, Hiroshi Hikakawa, Ryuji Yasumatsu, Ling-Yi L. Chang, Richard A Pierce, James D. Crapo, and Sule Cataltepe

Abstract

Recent studies in animal models of bronchopulmonary dysplasia (BPD) suggest that antioxidant treatments may be beneficial for the disease. However, the mechanisms by which these drugs improve the course of BPD are not completely known. Alpha1-antitrypsin (α1-AT) is one of the major serine protease inhibitors in human plasma that has anti-elastase and anti-apoptotic activities. Both activities of α1-AT are dependent on its reactive site loop (RSL), which is highly susceptible to oxidative inactivation. In this study, we investigated the elastase inhibitory activity of α1-AT in two different baboon models of BPD, the “new BPD” and the “severe BPD” models, and determined the effect of treatment with a catalytic antioxidant, Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP), on the elastase inhibitory activity of α1-AT in the severe BPD model. Our results demonstrate the presence of sufficient elastase inhibitory activity of the airway α1-AT in the new, but not the severe BPD model. Treatment of severe BPD group baboons with the catalytic antioxidant MnTE-2-PyP resulted in augmentation of the elastase inhibitory activity of α1-AT. These findings suggest that prevention of the oxidative inactivation of α1-AT may be one of the mechanisms by which antioxidant therapy improves the pulmonary outcomes in animal models of severe BPD.

Introduction

Bronchopulmonary dysplasia (BPD) remains as the most common complication of very preterm birth (reviewed in (1–5)). Infants with BPD not only suffer from long-term pulmonary dysfunction, but are also at higher risk of having growth restriction and adverse neurodevelopmental outcomes compared with age-matched infants (6–11). The pathogenesis of BPD is multifactorial and complex. Barotrauma, volutrauma, oxygen toxicity, antenatal
and postnatal inflammation, and patent ductus arteriosus have been implicated to play a role in the development of BPD (reviewed in (1, 5, 12)). An enhanced inflammatory reaction with persistent influx of neutrophils is observed in the airways of preterm infants, who subsequently develop BPD (13, 14). This inflammation is associated with an abundance of reactive oxygen species and proteases that may not be sufficiently regulated by antioxidants and antiproteases, respectively, of the preterm lung (15–17).

Several studies in animal models of BPD have demonstrated structural and functional improvements with antioxidant treatments. Transgenic newborn mice that overexpress human extracellular superoxide dismutase (SOD) demonstrated reduced inflammation, improved epithelial cell proliferation and preservation of alveolar surface and volume density when exposed to hyperoxia (18, 19). In hyperoxia-exposed baboons, intravenous treatment with a catalytic antioxidant, MnTE-2-PyP (Mn(III)meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin), resulted in improved alveolar surface area, decreased parenchymal mast cells, eosinophils, and neuroendocrine cells and urine bombesin-like-peptide levels (20). In a multicenter trial, treatment of premature infants with intratracheal recombinant human CuZn superoxide dismutase (r-CuZnSOD) failed to decrease the incidence of death or BPD, but resulted in a significant decrease in the number of patients who required asthma medications, had wheezing episodes, emergency room visits, or rehospitalizations at 1 year corrected gestational age compared with the controls (21). Thus although this study indicates that treatment with r-CuZnSOD may reduce lung injury, it is not clear why it did not have an effect on BPD incidence. Furthermore, the mechanisms by which antioxidant agents decrease inflammation and improve alveolarization in animal models are not completely understood.

Alpha1-antitrypsin (α1-AT) is one of the major serine protease inhibitors (serpin) in human plasma and has been a molecule of interest in BPD as one of the major inhibitors of neutrophil elastase (NE). In a study by Stiskal et al, i.v. administration of α1-AT to premature infants with respiratory distress syndrome decreased the incidence of pulmonary hemorrhage without having an effect on the incidence of BPD (22). In addition to its anti-elastase activity, recent studies have also identified a novel role for α1-AT in apoptosis as an inhibitor of caspase-3 (23–25). Similar to its anti-elastase activity, the anti-apoptotic activity of α1-AT is dependent on its reactive site loop (RSL), which is highly susceptible to oxidative inactivation (24). In this study, we investigated the elastase inhibitory activity of airway α1-AT in two different baboon models of BPD and determined the effect of the catalytic antioxidant, MnTE-2-PyP, on the elastase inhibitory activity of α1-AT recovered from the airways of baboons with hyperoxia-induced severe BPD.

**Methods**

**Animal Model**

Frozen baboon lung tissue and necropsy bronchoalveolar lavage fluid (BALF) samples were provided by the Southwest Foundation for Biomedical Research (San Antonio, TX). All animal procedures were reviewed and approved by the animal care committees of the Southwest Foundation for Biomedical Research and the University of Texas Health Science Center in San Antonio. In the new BPD model, baboons that were delivered by hysterotomy at 125 days were intubated, treated with exogenous surfactant (Survanta®; donated by Ross Laboratories, Columbus, OH) and maintained on pressure-limited, time-cycled infant ventilators (donated by InfantStar; Infrasonics, San Diego, CA) for 2 d, 6 d, or 14 d (new BPD group). The ventilator settings were adjusted to maintain the arterial carbon dioxide tension (PaCO₂) between 45 and 55 mmHg and oxygen was provided on a pro re nata (PRN) basis to maintain the arterial oxygen tension (PaO₂) between 55 and 70 mmHg. Animals that were sacrificed at 14 d had pathologic and biochemical findings that were characteristic of

*Pediatr Res.* Author manuscript; available in PMC 2012 October 1.
the new BPD seen in human infants as described previously (26). Baboons that were
delivered at 125-d or 140-d and sacrificed immediately served as the gestational controls
(125-d GC or 140-d GC groups). A third control group consisted of baboons that were born
via natural delivery at full-term gestation (~185 d) and sacrificed 2–3 days later (full-term
group). In the “severe BPD” model, baboons were delivered at 140 d gestation and were
ventilated for a total of 10 d with 100% O₂ (27). The catalytic antioxidant MnTE-2-PyP was
administered to 7 baboons that were exposed to 100% O₂ continuously. Since MnTE-2-PyP
has a half-life of 0.5 to 1 hour in mice, it was administered by continuous intravenous
infusion at a dose of 0.5 mg/kg/day using an infusion rate of 0.1 cc/hour as previously
described (20). A preliminary 2-week toxicity study in mice using continuous infusion of the
drug demonstrated no toxic effects at 5 mg/kg/day. Therefore a 10-fold lower dose was
chosen for this initial study in immature baboons.

**Isolation of total RNA and Reverse Transcription**

Total RNA was isolated from fresh-frozen baboon lung (right middle lobe) or liver tissues
using Trizol reagent (Invitrogen, Carlsbad, CA) and was treated with DNase I (Invitrogen)
following the manufacturer’s instructions. First-strand cDNA was synthesized from 0.5 µg
of RNA using the Superscript First-Strand Synthesis System (Invitrogen) with 0.5 µg oligo-
dT. The reaction mixture was incubated at 42°C for 50 min followed by incubation at 72°C
for 15 min. cDNA was stored at −20°C until use.

**Real-time PCR**

Real-time PCR analysis was performed using the Mx4000 Multiplex Quantitative PCR
System (Stratagene Inc, La Jolla, CA) and the brilliant SYBR Green QPCR Master Mix
(Stratagene Inc). The sequences of PCR primers were designed using the IDT DNA web site
(http://www.idtdna.com) and were as follows: alpha1-antitrypsin forward primer, 5’-
AGGAGCTTGACAGAGACACAGT-3’, reverse primer, 5’-
TCGGTGTCCTTGACTTCAAAGG-3’; cyclophilin A forward primer, 5’-
TTCATCTGCACTGCCAAGACTG-3’, reverse primer, 5’-GCG CTC CAC AAT ATT
CAT GCC T-3’. For PCR analysis, 2 µl cDNA was diluted 1:10, and the reactions were
performed in 20 µl of reaction volume with the following conditions: initial denaturation at
95°C for 10 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 62°C
for 60 s, and extension at 72°C for 30 s. All reactions were performed in triplicates and
repeated at least 3 times. Cyclophilin A was used as an internal reference to normalize the
target transcripts using the 2−ΔΔCT method (28, 29).

**Baboon bronchoalveolar lavage fluid**

BALF samples were obtained at the time of necropsy. Sterile 0.9% saline was instilled into
the left lower lobe until the lobe was completely filled and drawn back a total of five times.
BALF samples were centrifuged and supernatants were stored at −80°C until use. Total
protein concentration was determined by Bradford’s Assay (Bio-Rad, Hercules, CA). The
concentration of each sample was adjusted to 0.8 µg/µl either by adding PBS or by
concentrating the sample using a Vivaspin Concentrator (ISC Bio Express, Kaysville, UT)
according to the manufacturer’s protocol.

**Determination of the elastase inhibitory activity of α1-AT in BALF by formation of NE/α1-
AT complexes**

Bronchoalveolar lavage fluids (10 µl, total protein concentration, 0.8 µg/µl) were incubated
with two different concentrations of purified neutrophil elastase (2 µl of 16 ng/µl or 4 ng/µl,
Athens Research, Athens, GA) or the same volume of PBS, pH 7.4, for 15 min at room
temperature (RT). The samples were heated to 95°C in 2x Laemmli sample buffer for 5 min
and subjected to immunoblotting as previously described (16). Briefly, the proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked in a buffer containing PBS, pH 7.4, 0.1% Tween-20, and 5% dried milk for 1 h and incubated with a rabbit anti-human α1-AT polyclonal antibody at a dilution of 1 in 8000 (Sigma, St. Louis, MO) for 1 h at RT. Subsequently, the membrane was rinsed in wash buffer and incubated for 1 h with horseradish peroxidase-conjugated anti-rabbit IgG (Jackson Immunoresearch Laboratories, Westgrove, PA). After three rinses in wash buffer, the protein bands were visualized by chemiluminescence (ECL Western Blotting Analysis System; Amersham Biosciences, Piscataway, NJ).

**Statistical analysis**

Mann-Whitney U test and Fisher’s exact test were used for analysis of non-parametric and categorical data, respectively. Non-categorical data are presented as mean ± SEM and p < 0.05 is considered to be significant.

**Results**

**Effect of gestational age and BPD on airway α1-antitrypsin**

We first determined the relative antigenic levels of α1-AT in necropsy BALF obtained from premature and full-term control baboons, and baboons with BPD by immunoblotting. Control premature baboons were delivered and sacrificed at 125 d or 140 d. Bronchopulmonary dysplasia groups included two different models. In the first model, animals were delivered at 125 d and treated with one dose of surfactant, mechanical ventilation and as needed (PRN) O₂ for 14 d. This model induces lung injury that recapitulates the interrupted alveolarization and vascularization observed in human infants with “new BPD.” In the second model, baboons were delivered at 140-d gestation and exposed to 100% O₂ for 10 days. This model results in lung injury that is consistent with hyperoxia-induced severe BPD. Seven baboons from this group were treated with the catalytic antioxidant MnTE-2-PyP as a continuous infusion for 10 days.

Alpha1-antitrypsin was detected primarily as a 52 kDa band in all control BALF samples (Fig. 1, black arrow). All samples also contained lower molecular mass bands, likely due to proteolytic cleavage of α1-AT (Fig. 1, white arrow). In both BPD groups, there were increased levels of α1-AT compared with the control samples. In addition, BPD samples demonstrated more cleavage products compared with the control samples. There were no obvious differences in quantity or quality of α1-AT bands between the 125-d/PRN O₂ and 140-d/100% O₂ BPD models.

**Synthesis of α1-antitrypsin in baboon lung and liver tissues**

There are three major mechanisms that can lead to increased levels of α1-AT, a plasma serpin, in the airways of baboons with BPD. The first is the leakage of the protein into the airways as a result of impaired alveolar-capillary integrity, a well-known feature of several inflammatory lung diseases including BPD. Other possibilities include increased local production of α1-AT, for example by airway epithelial cells, and increased synthesis in the liver. To explore the latter two possibilities, we performed real-time PCR for α1-AT using baboon lung and liver cDNA samples. The relative steady-state mRNA levels of α1-AT in the lung were very low without any major differences among the groups (data not shown). In the liver, α1-AT mRNA levels were comparable in 140-d gestational control animals and BPD animals and higher than full-term animals, however this difference did not reach statistical significance (Fig. 2, p = 0.05). In the 140-d severe BPD group, α1-AT mRNA levels were lower than in the 125-d new BPD group, but this difference also did not reach statistical significance (p = 0.05). These data suggest that alterations in lung or liver mRNA
synthesis of α1-AT are unlikely to account for the increased levels of α1-AT in the airways in BPD.

**Functional activity of airway α1-antitrypsin in BPD**

Proteolytic degradation and oxidative inactivation are two major mechanisms that regulate the activity of serpins. We detected a 52 kDa full-length α1-AT molecule in all BPD BALF samples along with some cleaved forms. The 52 kDa band could represent either functionally active native α1-AT or its inactive oxidized form. To determine the functional activity of α1-AT, we incubated BALF samples with exogenous NE and assessed whether α1-AT formed SDS-stable high molecular mass complexes with NE (Fig. 3A and Table 1). This method allowed us to specifically assess the NE-neutralizing activity of α1-AT rather than other potential inhibitors of NE in BALF, such as SerpinB1 (30). All full-term control BALF samples demonstrated the presence of functionally active α1-AT by formation of a high molecular mass complex upon incubation with NE (Fig. 3A, arrowhead). In the new BPD group, we tested the elastase inhibitory activity of BALF samples obtained following 2 d (n=3), 6 d (n=3), and 14 d (n=5) of ventilation and PRN O2 treatment. All 2-d and 6-d samples, and 80% of the 14-d BALF samples contained functionally active α1-AT as indicated by the detection of high molecular mass bands (Fig.3A, arrowhead). In contrast, high molecular mass complexes were detected in only 33% of the BALF samples from hyperoxia-induced severe BPD group animals (n=6). Remarkably, all BALF samples obtained from hyperoxia-exposed and MnTE-2-PyP-treated baboons demonstrated the presence of α1-AT with NE-inhibitory activity as evidenced by formation of high molecular mass complexes upon incubation with α1-AT (n=7, p < 0.05 vs 100% O2 treated group, Fisher’s exact test, Fig. 3B).

**Discussion**

In this study, we determined the relative antigenic and functional levels of airway α1-AT in two different baboon models of BPD and evaluated the effect of a catalytic antioxidant, MnTE-2-PyP, on the activity of α1-AT in the “severe BPD” model. An imbalance between neutrophil elastase and its major endogenous inhibitor α1-AT was proposed to play a role in the development of BPD more than 25 years ago (31). Since then major advances in neonatology have led to a significant improvement in the clinical severity, but not the incidence of this disease. In the majority of surfactant-treated baboon and human infants with evolving BPD, NE is no longer the major offending protease (16, 30, 32, 33). Consistent with these observations, we found increased levels of functionally active α1-AT in the airways in the new BPD model, which indicates the presence of adequate elastase inhibitory activity. Our results also suggest that the increased airway levels of α1-AT in BPD are likely due to increased alveolar-capillary permeability rather than increased transcription of α1-AT in the lung or liver in this model although we can not rule out the possibility of increased mRNA or protein stability.

In baboon BALF samples, we detected only native and cleaved, but not complexed forms of α1-AT. The presence of cleaved forms of α1-AT can be explained by 3 potential mechanisms: cleavage of α1-AT by non-cognate proteases, such as cysteine proteases; cleavage of oxidized α1-AT by target proteases, such as NE; and cleavage of the 4 kDa COOH-terminal fragment as a result of complex formation between α1-AT and a target protease, thus yielding a ~ 48 kDa cleaved protein. In untreated BALF samples, some of the cleaved forms of α1-AT were the same size as the cleaved α1-AT (48 kDa) following *in vitro* complex formation between recombinant α1-AT and purified NE (Fig. 3). This suggests that these samples might have contained complexed α1-AT that was subsequently degraded during the retrieval process or storage of BALF.
Despite all advances in neonatology, a subgroup of extremely low birth weight infants continues to develop severe BPD following respiratory distress syndrome that may be complicated by sepsis, medical treatment-refractory patent ductus arteriosus, and/or pulmonary interstitial emphysema (34). The severe inflammatory response and treatment with high concentrations of oxygen in these fragile patients are inevitably associated with production of abundant reactive oxygen species and oxidant injury (15, 35). Our findings in the “severe BPD” model indicate that although the airway antigenic levels of $\alpha_1$-AT are similar to those in the new BPD model, the $\alpha_1$-AT recovered from the BALF of these animals does not have adequate elastase inhibitory activity as it fails to form SDS-stable complexes with exogenous NE. Since the majority of airway $\alpha_1$-AT in severe BPD was detected as a full-length 52 kDa band by immunoblotting, we reasoned that oxidative inactivation was a likely cause for failure of $\alpha_1$-AT to form inhibitory complexes with NE in these samples. Oxidation of methionine in PI position of $\alpha_1$-AT converts this amino acid to Met-SO, thus resulting in a dramatic loss of functional activity (36). In a study that examined BAL protein oxidation in children with chronic lung disease, $\alpha_1$-AT was identified as one of the most sensitive proteins to oxidation in the airways (37). In another study, inactivation of $\alpha_1$-AT by smokers’ macrophages was prevented by addition of antioxidant enzymes such as superoxide dismutase and catalase (38). Consistent with our hypothesis and these previous studies, we detected active $\alpha_1$-AT in BALF of a significantly higher number of severe BPD-group baboons treated with the antioxidant MnTE-2-PyP compared with those who did not receive this treatment.

In summary, antioxidant treatment of baboons with severe BPD resulted in augmentation of the elastase inhibitory activity of airway $\alpha_1$-AT. Protection of the RSL of $\alpha_1$-AT against oxidative inactivation may be beneficial for anti-proteinase and anti-apoptotic effects of this serpin, both of which are relevant for the pathogenesis of BPD. Further studies are needed to determine whether preservation of the function of $\alpha_1$-AT is one of the potential mechanisms that contribute to the therapeutic effects of anti-oxidants in animal models of BPD and whether this approach could benefit human infants with evolving severe BPD.

Acknowledgments

We thank Dr. Richard Parad for his critical review of the manuscript. We also thank Vickie Winter and Dr. Jackie Coalson for provision of the baboon samples.

This study was supported by NIH HL075904 [to S.C.] and NIH HL63397 [to J.D.C.]

Abbreviations

- $\alpha_1$-AT: alpha-1 antitrypsin
- BALF: bronchoalveolar lavage fluid
- BPD: bronchopulmonary dysplasia
- GC: gestational control
- MnTE-2-PyP: Mn(III) mesotetakis(N-ethylpyridinium-2-yl)porphyrin
- NE: neutrophil elastase
- PRN: pro re nata
- RSL: reactive site loop
- RT: room temperature
References


Figure 1. Alpha1-antitrypsin in baboon BALF samples
BALF samples were collected at the time of necropsy from 125-d, 140-d, and full-term gestation baboons and baboons with new (125-d/14 d PRN O₂) or severe (140-d/100% O₂) BPD. Immunoblotting was performed for α1-AT using a polyclonal antibody. A representative immunoblot is shown. Black and white arrows indicate 52 kDa native α1-AT and cleaved α1-AT, respectively.
Figure 2. Steady-state relative mRNA levels of $\alpha$1-AT in baboon liver samples
Relative steady-state mRNA levels of $\alpha$1-AT in liver tissues were determined by real-time reverse transcription-PCR using RNA isolated from 140-d gestational control, full-term (FT), new (125-d/14 d PRN O$_2$) and severe (140-d/100% O$_2$) BPD group baboons. N=4–5 animals/group. Data is expressed as mean ± SEM from two independent experiments performed in triplicates.
Figure 3. Assessment of anti-neutrophil elastase activity by formation of high molecular mass complexes between α1-AT and exogenous neutrophil elastase in baboon BALF samples
(A) Recombinant α1-AT or baboon necropsy BALF samples were incubated with PBS or purified NE (32 ng) at RT for 15 min, then exposed to SDS-PAGE and immunoblotting using a polyclonal antibody for α1-AT under reducing conditions. A representative immunoblot is shown. Arrowhead, black arrow and white arrow indicate 81 kDa complexed α1-AT, 52 kDa native α1-AT, and cleaved α1-AT, respectively. (B) Representative immunoblot demonstrating α1-AT immunoreactivity in necropsy BALF samples of a baboon delivered at 140 d gestation and treated with mechanical ventilation and 100% O2 for 10 days and a baboon that received i.v. antioxidant MnTE-2-PyP for 10 days. Samples were incubated at RT for 15 min with PBS (lanes 1 and 4) or two different amounts of purified NE (32 ng, lanes 2 and 5, or 8 ng, lanes 3 and 6). Immunoblotting was performed under reducing conditions using a polyclonal antibody against α1-AT.
Table 1

Summary of α1-antitrypsin activity in necropsy bronchoalveolar lavage samples of baboons with BPD.

<table>
<thead>
<tr>
<th>BALF sample</th>
<th>125-d gestation/PRN O2 model (new BPD)</th>
<th>140d/100% O2 model (Severe BPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2-d (n=3)</td>
<td>Untreated (n=6)</td>
</tr>
<tr>
<td></td>
<td>6-d (n=3)</td>
<td>MnTE-2-PyP-treated (n=7)</td>
</tr>
<tr>
<td>Activity of α1-AT (%)</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

* Assessed by formation of high molecular mass complexes of α1-AT when treated with neutrophil elastase.

** $p < 0.05$ versus untreated group (Fisher’s exact test)